PolTREG S.A., a world leader in cell therapies based on T-regulator cells (TREGS), has received information about the recommendation for funding under the Horizon Europe program by the European Executive Agency for Health and Digitization of the project entitled “Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe),” in which the Company is a member of the consortium. The consortium includes internationally renowned French and German universities and biotechnology companies. The value of financing for the consortium is about EUR 7 million, while the subsidy attributable to PolTREG S.A. is about EUR 0.8 million. The financing constitutes 100% of the project expenses.